JP2017533895A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533895A5 JP2017533895A5 JP2017517315A JP2017517315A JP2017533895A5 JP 2017533895 A5 JP2017533895 A5 JP 2017533895A5 JP 2017517315 A JP2017517315 A JP 2017517315A JP 2017517315 A JP2017517315 A JP 2017517315A JP 2017533895 A5 JP2017533895 A5 JP 2017533895A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- reaction
- pharmaceutically acceptable
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 39
- 238000006243 chemical reaction Methods 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 238000002360 preparation method Methods 0.000 claims 7
- 238000009472 formulation Methods 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 208000027866 inflammatory disease Diseases 0.000 claims 5
- 230000000155 isotopic effect Effects 0.000 claims 5
- -1 4-((4- (3- (5- (tert-butyl) -2-methoxy-3- (methylsulfonamido) phenyl) ureido) naphthalen-1-yl) oxy) pyridin-2-yl Chemical group 0.000 claims 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 3
- 206010013774 Dry eye Diseases 0.000 claims 3
- 206010046851 Uveitis Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 206010023332 keratitis Diseases 0.000 claims 3
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 3
- 208000005494 xerophthalmia Diseases 0.000 claims 3
- 208000015943 Coeliac disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 208000001344 Macular Edema Diseases 0.000 claims 2
- 206010025415 Macular oedema Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 201000005667 central retinal vein occlusion Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 201000010230 macular retinal edema Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 208000004644 retinal vein occlusion Diseases 0.000 claims 2
- 238000000926 separation method Methods 0.000 claims 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 208000002691 Choroiditis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 206010011017 Corneal graft rejection Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012434 Dermatitis allergic Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022941 Iridocyclitis Diseases 0.000 claims 1
- 208000003971 Posterior uveitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 201000004612 anterior uveitis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 150000001540 azides Chemical class 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 208000029771 childhood onset asthma Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 201000007407 panuveitis Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims 1
- 230000008707 rearrangement Effects 0.000 claims 1
- 238000006462 rearrangement reaction Methods 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 0 Nc1ccc2C(O)=*c2c1 Chemical compound Nc1ccc2C(O)=*c2c1 0.000 description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1417344.7A GB201417344D0 (en) | 2014-10-01 | 2014-10-01 | New compounds |
| GB1417344.7 | 2014-10-01 | ||
| GB1510694.1 | 2015-06-18 | ||
| GBGB1510694.1A GB201510694D0 (en) | 2015-06-18 | 2015-06-18 | New compounds |
| PCT/GB2015/052877 WO2016051188A1 (en) | 2014-10-01 | 2015-10-01 | 4-(4-(4-phenylureido-naphthalen-1-yl)oxy-pyridin-2-yl)amino-benzoic acid derivative as p38 kinase inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533895A JP2017533895A (ja) | 2017-11-16 |
| JP2017533895A5 true JP2017533895A5 (OSRAM) | 2018-11-08 |
| JP6662863B2 JP6662863B2 (ja) | 2020-03-11 |
Family
ID=54337298
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017517315A Expired - Fee Related JP6662863B2 (ja) | 2014-10-01 | 2015-10-01 | Ｐ３８キナーゼ阻害剤としての４−（４−（４−フェニルウレイドナフタレン−１−イル）オキシピリジン−２−イル）アミノ安息香酸誘導体 |
| JP2017517316A Expired - Fee Related JP6608918B2 (ja) | 2014-10-01 | 2015-10-01 | Ｐ３８キナーゼ阻害剤としてのジアリール尿素誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017517316A Expired - Fee Related JP6608918B2 (ja) | 2014-10-01 | 2015-10-01 | Ｐ３８キナーゼ阻害剤としてのジアリール尿素誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (6) | US9499486B2 (OSRAM) |
| EP (2) | EP3201179A1 (OSRAM) |
| JP (2) | JP6662863B2 (OSRAM) |
| KR (2) | KR20170057445A (OSRAM) |
| CN (2) | CN106999478A (OSRAM) |
| AU (2) | AU2015326543B2 (OSRAM) |
| BR (2) | BR112017006073A2 (OSRAM) |
| CA (1) | CA2961870A1 (OSRAM) |
| EA (2) | EA035478B1 (OSRAM) |
| MA (2) | MA40775A (OSRAM) |
| MX (2) | MX2017004128A (OSRAM) |
| WO (2) | WO2016051187A1 (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5511680B2 (ja) | 2007-12-19 | 2014-06-04 | キャンサー・リサーチ・テクノロジー・リミテッド | ピリド［２，３−ｂ］ピラジン−８−置換化合物及びその使用 |
| NZ601085A (en) | 2010-02-01 | 2015-04-24 | Cancer Rec Tech Ltd | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy |
| EP2763984B1 (en) | 2011-10-03 | 2016-04-20 | Respivert Limited | 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 map kinase inhibitors |
| EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
| GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
| EP2890701B1 (en) | 2012-08-29 | 2017-03-29 | Respivert Limited | Kinase inhibitors |
| US20150210722A1 (en) | 2012-08-29 | 2015-07-30 | Respivert Limited | Kinase inhibitors |
| WO2014033447A2 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
| WO2014076484A1 (en) | 2012-11-16 | 2014-05-22 | Respivert Limited | Kinase inhibitors |
| US20160016934A1 (en) | 2013-03-14 | 2016-01-21 | Respivert Limited | Kinase inhibitors |
| BR112015024678B1 (pt) | 2013-04-02 | 2023-02-23 | Oxular Acquisitions Limited | Composto inibidor da cinase, formulação farmacêutica que compreende o mesmo, seus usos, processo para sua preparação e intermediários |
| US9771353B2 (en) | 2013-04-02 | 2017-09-26 | Topivert Pharma Limited | Kinase inhibitors based upon N-alkyl pyrazoles |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| JP6514703B2 (ja) * | 2013-12-20 | 2019-05-15 | トピバート ファーマ リミテッド | キナーゼインヒビターとして有用な尿素誘導体 |
| TWI664967B (zh) | 2014-02-14 | 2019-07-11 | 英商瑞斯比維特有限公司 | 新穎化合物（一） |
| MA40775A (fr) * | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38 |
| CA3015978A1 (en) * | 2016-04-06 | 2017-10-12 | Topivert Pharma Limited | Kinase inhibitors |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| PT3691620T (pt) | 2017-10-05 | 2022-10-06 | Fulcrum Therapeutics Inc | Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd |
| ES3025468T3 (en) | 2018-12-07 | 2025-06-09 | Univ Maryland | Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors |
| US20230072053A1 (en) * | 2020-01-29 | 2023-03-09 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2022204046A1 (en) * | 2021-03-23 | 2022-09-29 | Gen1E Lifesciences Inc. | Substituted naphthyl p38alpha mitogen-activated protein kinase inhibitors |
| WO2024229267A1 (en) * | 2023-05-02 | 2024-11-07 | Purdue Research Foundation | Diaryl urea-based compounds and related compositions and methods of use in the treatment of diabetes mellitus and neurodegenerative disease |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001521934A (ja) | 1997-11-03 | 2001-11-13 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 抗炎症薬としての芳香族ヘテロ環式化合物 |
| EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| ATE538794T1 (de) * | 1999-01-13 | 2012-01-15 | Bayer Healthcare Llc | Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer |
| UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
| ID30176A (id) | 1999-03-12 | 2001-11-08 | Boehringer Ingelheim Pharma | Senyawa-senyawa yang bermanfaat sebagai zat anti-inflamasi |
| EP1200411B1 (en) | 1999-07-09 | 2005-12-14 | Boehringer Ingelheim Pharmaceuticals Inc. | Process for synthesis of heteroaryl-substituted urea compounds |
| CA2389360C (en) * | 1999-11-16 | 2008-06-03 | Steffen Breitfelder | Urea derivatives as anti-inflammatory agents |
| US6492529B1 (en) | 2000-01-18 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Bis pyrazole-1H-pyrazole intermediates and their synthesis |
| US6525046B1 (en) | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
| EP1506962B1 (en) | 2000-10-20 | 2008-07-02 | Eisai R&D Management Co., Ltd. | Nitrogen-containing aromatic heterocycles |
| EP1381594A1 (en) | 2001-04-13 | 2004-01-21 | Boehringer Ingelheim Pharmaceuticals Inc. | Urea compounds useful as anti-inflammatory agents |
| WO2002083628A1 (en) | 2001-04-13 | 2002-10-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-disubstituted benzo-fused compounds |
| JP2004530690A (ja) | 2001-05-16 | 2004-10-07 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 抗炎症性薬剤として有用なジアリールウレア誘導体 |
| WO2002096876A1 (en) | 2001-05-25 | 2002-12-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Carbamate and oxamide compounds as inhibitors of cytokine production |
| ATE360417T1 (de) | 2001-07-11 | 2007-05-15 | Boehringer Ingelheim Pharma | Methode zur behandlung von zytokinvermittelten erkrankungen |
| US20040023961A1 (en) | 2002-02-11 | 2004-02-05 | Bayer Corporation | Aryl ureas with raf kinase and angiogenisis inhibiting activity |
| SI1478358T1 (sl) | 2002-02-11 | 2013-09-30 | Bayer Healthcare Llc | Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi |
| WO2003072569A1 (en) | 2002-02-25 | 2003-09-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases |
| AR037647A1 (es) * | 2002-05-29 | 2004-12-01 | Novartis Ag | Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina |
| AU2003257991A1 (en) | 2002-08-08 | 2004-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes |
| WO2004113352A1 (en) | 2003-06-19 | 2004-12-29 | Amedis Pharmaceuticals Ltd. | Silylated heterocyclylurea derivatives as cytokine-inhibitors |
| CN1812975A (zh) | 2003-06-30 | 2006-08-02 | 贝林格尔·英格海姆药物公司 | 制备二芳基脲化合物的方法 |
| BRPI0413757A (pt) | 2003-08-22 | 2006-10-31 | Boehringer Ingelheim Pharma | métodos para o tratamento de copd e da hipertensão pulmonar |
| CN102060806A (zh) | 2003-09-11 | 2011-05-18 | iTherX药品公司 | 细胞因子抑制剂 |
| WO2005044825A1 (en) | 2003-10-21 | 2005-05-19 | Amedis Pharmaceuticals Ltd. | Silicon compounds and their use |
| RU2006122853A (ru) * | 2003-11-28 | 2008-01-10 | Новартис АГ (CH) | Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы |
| GB0327734D0 (en) * | 2003-11-28 | 2003-12-31 | Novartis Ag | Organic compounds |
| US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
| GB0423554D0 (en) | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
| TW200740820A (en) | 2005-07-05 | 2007-11-01 | Takeda Pharmaceuticals Co | Fused heterocyclic derivatives and use thereof |
| PE20070795A1 (es) | 2005-10-28 | 2007-08-24 | Lilly Co Eli | Compuestos pirazol-urea-heterociclicos como inhibidores de cinasa |
| US7790756B2 (en) * | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| GB0818033D0 (en) | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
| PE20110598A1 (es) | 2008-10-02 | 2011-08-31 | Respivert Ltd | Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38 |
| MX2011006220A (es) | 2008-12-11 | 2011-06-28 | Respivert Ltd | Inhibidores de la proteina cinasa activada por el mitogeno p38. |
| GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| CA2760766A1 (en) * | 2009-05-21 | 2010-11-25 | Nicholas James Bennett | Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases |
| GB0921730D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Method of treatment |
| GB0921731D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Theraputic uses |
| GB201005589D0 (en) | 2010-04-01 | 2010-05-19 | Respivert Ltd | Novel compounds |
| JP5787977B2 (ja) | 2010-04-08 | 2015-09-30 | レスピバート・リミテツド | Ｐ３８ｍａｐキナーゼ阻害剤 |
| US9260410B2 (en) | 2010-04-08 | 2016-02-16 | Respivert Ltd. | P38 MAP kinase inhibitors |
| US8973435B2 (en) | 2010-05-11 | 2015-03-10 | Breville Pty Limited | Espresso machine method and apparatus |
| WO2011158044A2 (en) | 2010-06-17 | 2011-12-22 | Respivert Limited | Respiratory formulations and compounds for use therein |
| GB201010196D0 (en) | 2010-06-17 | 2010-07-21 | Respivert Ltd | Methods |
| GB201010193D0 (en) | 2010-06-17 | 2010-07-21 | Respivert Ltd | Medicinal use |
| EP2763984B1 (en) | 2011-10-03 | 2016-04-20 | Respivert Limited | 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 map kinase inhibitors |
| EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
| WO2013083604A1 (en) | 2011-12-09 | 2013-06-13 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
| GB201214750D0 (en) * | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
| WO2014033447A2 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
| US20150210722A1 (en) | 2012-08-29 | 2015-07-30 | Respivert Limited | Kinase inhibitors |
| GB201215357D0 (en) | 2012-08-29 | 2012-10-10 | Respivert Ltd | Compounds |
| EP2890701B1 (en) | 2012-08-29 | 2017-03-29 | Respivert Limited | Kinase inhibitors |
| WO2014076484A1 (en) | 2012-11-16 | 2014-05-22 | Respivert Limited | Kinase inhibitors |
| US20160016934A1 (en) | 2013-03-14 | 2016-01-21 | Respivert Limited | Kinase inhibitors |
| US9771353B2 (en) | 2013-04-02 | 2017-09-26 | Topivert Pharma Limited | Kinase inhibitors based upon N-alkyl pyrazoles |
| BR112015024678B1 (pt) | 2013-04-02 | 2023-02-23 | Oxular Acquisitions Limited | Composto inibidor da cinase, formulação farmacêutica que compreende o mesmo, seus usos, processo para sua preparação e intermediários |
| JP6514703B2 (ja) * | 2013-12-20 | 2019-05-15 | トピバート ファーマ リミテッド | キナーゼインヒビターとして有用な尿素誘導体 |
| EP3102283B1 (en) * | 2014-02-05 | 2018-02-28 | Boston Scientific Neuromodulation Corporation | System for delivering modulated sub-threshold therapy to a patient |
| TWI664967B (zh) | 2014-02-14 | 2019-07-11 | 英商瑞斯比維特有限公司 | 新穎化合物（一） |
| MA40775A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38 |
| EP3201189A1 (en) | 2014-10-01 | 2017-08-09 | Respivert Limited | N-phenyl-3-quinazolin-6-yl-benzamide derivatives as p38 kinase inhibitors |
-
2015
- 2015-09-30 MA MA040775A patent/MA40775A/fr unknown
- 2015-09-30 MA MA040774A patent/MA40774A/fr unknown
- 2015-10-01 US US14/872,807 patent/US9499486B2/en not_active Expired - Fee Related
- 2015-10-01 BR BR112017006073A patent/BR112017006073A2/pt not_active Application Discontinuation
- 2015-10-01 JP JP2017517315A patent/JP6662863B2/ja not_active Expired - Fee Related
- 2015-10-01 EP EP15782017.6A patent/EP3201179A1/en not_active Withdrawn
- 2015-10-01 WO PCT/GB2015/052876 patent/WO2016051187A1/en not_active Ceased
- 2015-10-01 MX MX2017004128A patent/MX2017004128A/es unknown
- 2015-10-01 CN CN201580053439.3A patent/CN106999478A/zh active Pending
- 2015-10-01 CA CA2961870A patent/CA2961870A1/en active Pending
- 2015-10-01 MX MX2017004129A patent/MX373658B/es active IP Right Grant
- 2015-10-01 EA EA201790658A patent/EA035478B1/ru not_active IP Right Cessation
- 2015-10-01 KR KR1020177011685A patent/KR20170057445A/ko not_active Ceased
- 2015-10-01 EA EA201790660A patent/EA032694B1/ru not_active IP Right Cessation
- 2015-10-01 AU AU2015326543A patent/AU2015326543B2/en not_active Ceased
- 2015-10-01 JP JP2017517316A patent/JP6608918B2/ja not_active Expired - Fee Related
- 2015-10-01 CN CN201580053462.2A patent/CN107001274A/zh active Pending
- 2015-10-01 KR KR1020177010961A patent/KR20170063783A/ko not_active Withdrawn
- 2015-10-01 WO PCT/GB2015/052877 patent/WO2016051188A1/en not_active Ceased
- 2015-10-01 BR BR112017005531A patent/BR112017005531A2/pt not_active Application Discontinuation
- 2015-10-01 EP EP15782018.4A patent/EP3201180A1/en not_active Withdrawn
- 2015-10-01 US US14/872,527 patent/US9751837B2/en not_active Expired - Fee Related
- 2015-10-01 AU AU2015326614A patent/AU2015326614B2/en not_active Ceased
-
2016
- 2016-10-12 US US15/291,359 patent/US9822076B2/en active Active
-
2017
- 2017-05-24 US US15/604,258 patent/US10125100B2/en active Active
-
2018
- 2018-07-13 US US16/035,502 patent/US10392346B2/en active Active
-
2019
- 2019-07-10 US US16/508,253 patent/US10941115B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017533895A5 (OSRAM) | ||
| JP2016519680A5 (OSRAM) | ||
| US11753399B2 (en) | Therapeutic compounds | |
| JP6608918B2 (ja) | Ｐ３８キナーゼ阻害剤としてのジアリール尿素誘導体 | |
| JP2017535525A5 (OSRAM) | ||
| JP2013545818A5 (OSRAM) | ||
| JP6464384B2 (ja) | キナーゼ阻害剤 | |
| TWI259079B (en) | N-biphenyl(substituted methyl)aminocycloalkanecarboxamide derivatives | |
| JP2013545817A5 (OSRAM) | ||
| JP2020518581A5 (OSRAM) | ||
| JP2019517463A5 (OSRAM) | ||
| JP2013545816A5 (OSRAM) | ||
| JP2012530713A5 (OSRAM) | ||
| CA2954751A1 (en) | Indoles for use in influenza virus infection | |
| JP2017502033A5 (OSRAM) | ||
| TW201034669A (en) | Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors | |
| JP2009524611A5 (ja) | Ｓ１ｐ１受容体アゴニスト、免疫抑制剤および抗炎症剤としての３，５ージ（アリールまたはヘテロアリール）イソキサゾールおよび１，２，４−オキサジアゾール | |
| TW200304824A (en) | Nicotinamide derivatives useful as PDE4 inhibitors | |
| JP2010516700A5 (OSRAM) | ||
| JP2019514861A5 (OSRAM) | ||
| NZ735093A (en) | Inhibitors of hepatitis c virus polymerase | |
| IL296182A (en) | Inhibitors of human immunodeficiency virus replication | |
| TWI694986B (zh) | 經取代之吡啶基-環烷基-羧酸、包含其之組合物及其用途 | |
| WO2015044170A1 (de) | Substituierte phenylalanin-derivate und ihre verwendung zur behandlung von thrombotischen / thromboembolischen erkrankungen | |
| CN103097365B (zh) | 作为鞘氨醇-1-磷酸(s1p)受体上的配体的5-(联苯-4-基)-3-苯基-1,2,4-噁二唑基衍生物 |